It’s a good day to be an Compass Therapeutics Inc (CMPX) shareholder

The closing price of Compass Therapeutics Inc (NASDAQ: CMPX) was $1.98 for the day, down -3.41% from the previous closing price of $2.05. In other words, the price has decreased by -$0.0700 from its previous closing price. On the day, 176553 shares were traded.

Ratios:

Our analysis of CMPX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.73 and its Current Ratio is at 19.73. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on January 31, 2023, initiated with a Buy rating and assigned the stock a target price of $8.

On January 27, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $9.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 282.06M and an Enterprise Value of 131.33M.

Stock Price History:

Over the past 52 weeks, CMPX has reached a high of $3.62, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 1.7321, while the 200-Day Moving Average is calculated to be 2.0644.

Shares Statistics:

CMPX traded an average of 517.50K shares per day over the past three months and 382.89k shares per day over the past ten days. A total of 127.67M shares are outstanding, with a floating share count of 82.14M. Insiders hold about 40.30% of the company’s shares, while institutions hold 40.89% stake in the company. Shares short for CMPX as of Mar 15, 2024 were 1.88M with a Short Ratio of 3.64, compared to 1.97M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.37% and a Short% of Float of 1.86%.

Earnings Estimates

The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.12, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.13.

Analysts are recommending an EPS of between -$0.45 and -$0.53 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.5, with 7 analysts recommending between -$0.39 and -$0.79.

Most Popular